The effect of acetazolamide in patients with renal involvement

Comparison of the effectiveness of acetazolamide and placebo in diuresis of patients with treatment-resistant oliguria with diuretics in the intensive care unit

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240514061790N1

Enrollment

130

Registered

2024-10-08

Start date

2023-11-24

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diuretics resistant oliguria. Anuria and oliguria

Interventions

Intervention 1: Intervention group: Acetazolamide 250 tablets orally every 12 hours for two days. Intervention 2: Control group: placebo tablet similar to acetazolamide 250 mg every 12 hours for 2 day

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age above 18 years Being satisfied with participation in the study Oliguric patients resistant to diuretics

Exclusion criteria

Exclusion criteria: Hypokalemia and hyponatremia Metabolic acidosis Patients with skin sensitivity and allergies Liver disease and cirrhosis End Stage Renal Disease (ERDS)

Design outcomes

Primary

Measure	Time frame
Percentage of patients with oliguria status to diuretic. Timepoint: On the second and third days, examining the amount of diuresis in patients receiving acetazolamide compared to patients receiving placebo. Method of measurement: Urine bag.	—

Secondary

Measure	Time frame
Organ damage. Timepoint: The beginning of the study and 4 days after the start of the study. Method of measurement: SOFA and APACHE scoring system.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoghayeh asghari

Tabriz University of Medical Sciences

Asghari1380@yahoo.com+98 41 3331 4165

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026